Working… Menu
Trial record 55 of 1542 for:    Androgens

A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01337518
Recruitment Status : Suspended (Reassessment of strategic direction)
First Posted : April 19, 2011
Last Update Posted : December 18, 2012
Information provided by (Responsible Party):
Enzon Pharmaceuticals, Inc.

Brief Summary:
This study will evaluate an experimental drug called EZN-4176 to determine the anticancer effects when it is given to patients with an advanced form of prostate cancer called castration-resistant prostate cancer (CRPC). Goals of this phase I study include finding out the dose of EZN-4176 that can be safely given without serious side effects and to determine the amount of EZN-4176 that should be given in future studies.

Condition or disease Intervention/treatment Phase
Prostatic Neoplasm Drug: EZN-4176 Phase 1

Detailed Description:

This study will be conducted in two phases:

  • Phase 1a will involve dose escalation to determine the maximum tolerated dose (MTD). The MTD will be determined on the basis of the results from the safety evaluation.
  • Phase 1b will involve cohort expansion at one or more dose levels to determine the recommended Phase 2 dose. The recommended Phase 2 dose, which may differ from the MTD, will be determined on the basis of results from safety, activity, and pharmacologic and correlative studies.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1a/1b, Open-Label Study Evaluating the Safety and Tolerability of EZN-4176, an Androgen Receptor mRNA Antagonist, in Adult Patients With Castration-Resistant Prostate Cancer
Study Start Date : March 2011
Estimated Primary Completion Date : December 2013
Estimated Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: EZN-4176 Drug: EZN-4176
EZN-4176 can be administered as a weekly one-hour i.v. infusion; weekly for 3 weeks followed by a 1 week rest; or 1 out of 2 weeks (every other week)
Other Name: Androgen Receptor mRNA Antagonist

Primary Outcome Measures :
  1. Determine the Maximum Tolerated Dose (MTD) of EZN-4176 administered as a weekly 1-hour IV infusion. [ Time Frame: 2012 ]
    Evaluate incidence, severity and duration of adverse events using National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], Version 4.0, during first cycle.

Secondary Outcome Measures :
  1. Determine the recommended Phase 2 dose of EZN-4176 [ Time Frame: 2013 ]
    Incidence, severity and duration of adverse events using National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], Version 4.0, during all cycles; Objective response, as assessed per recommendations of the Prostate Cancer Clinical Trials Working Group (PCWG2).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Capable of understanding protocol requirements & risks & providing written informed consent
  2. Histologically or cytologically confirmed diagnosis of metastatic prostate adenocarcinoma
  3. Ongoing gonadal androgen-deprivation therapy with LHRH analogs or orchiectomy. Patients without orchiectomy must receive effective LHRH analog therapy during the study
  4. Testosterone < 50 ng/dL
  5. Progressive disease after androgen deprivation - with all 3 of the following criteria:PSA evidence of progressive prostate cancer; PSA ≥ 5 ng/mL increasing on at least 2 successive occasions, at least 2 weeks apart. If confirmatory PSA < screening PSA, additional test for increasing PSA is needed
  6. Patients receiving anti-androgen agent as part of primary androgen ablation: disease progression after stopping the anti-androgen agent. This disease progression is defined: 2 consecutive increasing PSAs ≥ 2 weeks apart, or documented osseous or soft tissue progression. Flutamide patients: at least one of the PSAs ≥ 4 weeks after stopping flutamide. Bicalutamide or nilutamide patients: at least one PSA ≥ 6 weeks after stopping the anti-androgen agent.
  7. Patients who failed standard therapy or who, after physician discussion, wish to delay chemotherapy
  8. Age ≥ 18 yrs
  9. ECOG Score: 0-1
  10. Albumin ≥3.0 g/dL
  11. ANC ≥ 1,500/µL
  12. Plts ≥ 75,000/µL
  13. Hgb ≥ 9.0 g/dL
  14. Serum Creat. ≤ 1.5xULN or Calc Creat. clearance ≥ 60 mL/min
  15. Tot bili ≤ 1.5xULN
  16. AST; ALT: ≤ 2.5xULN

Exclusion Criteria:

  1. Prostate cancer other than adenocarcinoma, eg. neuroendocrine or small cell histology
  2. Concurrent serious medical illness that might interfere with protocol compliance
  3. Known chronic infectious disease, eg. AIDS or hepatitis
  4. Male patient of reproductive capacity unwilling to use methods appropriate to prevent pregnancy. In the UK, double-barrier contraception required. Patients should continue to use contraception for 3 months after stopping EZN-4176 due to potential for prolonged half-life of EZN-4176 in the liver.
  5. History of CNS tumor involvement
  6. Other hormonal therapy, eg. megestrol acetate (Megace®), finasteride (Proscar®), dutasteride (Avodart®), or any herbal product known to decrease PSA (e.g., saw palmetto, PC-SPES, and PC-HOPE)
  7. > 10 mg/day of prednisone or equivalent systemic corticosteroid within 4 weeks of first dose of EZN-4176
  8. Initiation of bisphosphonates within 4 weeks of enrollment. Patients receiving stable doses of bisphosphonates with subsequent tumor progression may continue to receive this medication; however, initiation of bisphosphonates is not allowed during the study.
  9. Therapy with supplements or complementary medicines/botanicals within 4 weeks of first dose of study drug, except for any combination of the following: Conventional multivitamin supplements; Selenium; Lycopene; and Soy supplements
  10. Prior chemotherapy, immunotherapy, investigational therapeutic agent, or other therapy used to treat the cancer within 4 weeks (6 weeks for prior treatment with mitomycin C or nitrosoureas) before first dose of EZN-4176
  11. Radiation or radioactive treatment within 4 weeks before first dose of EZN-4176. Single-fraction palliative radiation is allowed within 2 weeks before first dose of EZN-4176
  12. Lack of recovery from any reversible side effects (except alopecia and Grade 1 or 2 neuropathy) to Grade 0 or 1 toxicity related to administration of an investigational therapeutic agent, chemotherapy, immunotherapy, radiotherapy, or other agents previously used to treat the cancer
  13. Current participation in another clinical study with an investigational therapeutic agent and/or use of an investigational therapeutic drug (not including investigational use of an approved drug) in the 30 days before first dose of EZN-4176
  14. Inability to comply with study protocol
  15. Full anticoagulation therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01337518

Layout table for location information
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
United Kingdom
Institute of Cancer Research, Royal Marsden Hospital
Sutton, Surrey, United Kingdom, SM2 5PT
Sponsors and Collaborators
Enzon Pharmaceuticals, Inc.
Layout table for investigator information
Study Director: Aby Buchbinder, MD Enzon Pharmaceuticals, Inc.
Principal Investigator: Daniel Danila, MD Memorial Sloan Kettering Cancer Center
Principal Investigator: Johann de Bono, MD Institute of Cancer Research, Royal Marsden Hospital

Layout table for additonal information
Responsible Party: Enzon Pharmaceuticals, Inc. Identifier: NCT01337518     History of Changes
Other Study ID Numbers: EZN-4176-01
First Posted: April 19, 2011    Key Record Dates
Last Update Posted: December 18, 2012
Last Verified: September 2012
Keywords provided by Enzon Pharmaceuticals, Inc.:
Prostate Specific Antigen
Castration Resistant Prostate Cancer
Androgen Receptor
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs